Abstract

Background

Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes the psychosocial burden of AA.

Methods

Participants diagnosed with AA who had experienced ≥50% scalp hair loss according to the Severity of Alopecia Tool (SALT) were identified by clinicians. A semi-structured interview guide, developed with expert clinician input, included open-ended questions to explore patients’ experiences of living with AA. Data were thematically analyzed to identify concepts and relationships.

Results

Participants (n = 45, 58% female, mean age 33.3 years [range 15–72], mean SALT 67.2 [range 0–100]) described the AA diagnosis as “devastating”. Both males and females reported emotional and psychological impacts of AA including feeling sad/depressed (n = 21), embarrassed/ashamed (n = 10) and angry/frustrated (n = 3). Patients felt helpless (n = 5) due to the unpredictability of disease recurrence, and anxious (n = 19) about judgement from others. Many patients avoided social situations (n = 18), which impaired relationships and increased isolation. Coping strategies included concealment of hair loss through wigs or make-up, although fear of the displacement of these coverings also caused anxiety and the avoidance of activities that could result in scalp exposure (n = 22). Some patients became more accepting of AA over time, which lessened the emotional impact, though efficacious treatment was still desired. A conceptual framework was developed, and a conceptual model was created to depict the relationship between the physical signs/symptoms and the associated psychosocial effects of AA.

Conclusion

AA impairs patients’ emotional and psychological wellbeing, relationships and lifestyles. Greater disease awareness and effective treatments are needed.

Details

Title
“‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
Author
Aldhouse Natalie V J 1   VIAFID ORCID Logo  ; Kitchen, Helen 1   VIAFID ORCID Logo  ; Knight, Sarah 1   VIAFID ORCID Logo  ; Macey Jake 1   VIAFID ORCID Logo  ; Nunes, Fabio P 2   VIAFID ORCID Logo  ; Dutronc Yves 2   VIAFID ORCID Logo  ; Mesinkovska Natasha 3   VIAFID ORCID Logo  ; Ko, Justin M 4   VIAFID ORCID Logo  ; King, Brett A 5   VIAFID ORCID Logo  ; Wyrwich, Kathleen W 6   VIAFID ORCID Logo 

 Clinical Outcomes Assessment, DRG Abacus (part of Clarivate), The Lexicon, Manchester, UK 
 Lilly Corporate Center, Lilly Bio-Medicines, Eli Lilly and Company, Eli Lilly and Company, Indianapolis, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544) 
 Hewitt Hall Building, University of California Irvine Dermatology Clinical Research Center, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243) 
 Stanford University School of Medicine, Stanford Dermatology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Yale School of Medicine, Department of Dermatology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Lilly Corporate Center, Patient-Focused Outcomes Center of Expertise, Eli Lilly and Company, Indianapolis, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544) 
Publication year
2020
Publication date
Dec 2020
Publisher
Springer Nature B.V.
e-ISSN
25098020
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2441384542
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.